Want to see TSE:PREV full AI Analyst Report?
Top Page
PreveCeutical Medical
(PREV)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.03
▲(25.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by very weak financial performance (no revenue, persistent losses, negative equity, and ongoing free-cash-flow burn). Technicals provide a meaningful offset with bullish momentum versus key moving averages and a positive MACD. Valuation remains a headwind because the negative P/E reflects continued unprofitability and there is no dividend yield support.
Positive Factors
Drug-delivery and therapeutic R&D platform
A focused portfolio spanning therapeutic formulations and delivery technologies provides multiple routes to future commercialization, licensing, or partnering. If development milestones are achieved, this platform could create intellectual-property value beyond any single product candidate over the next several quarters.
Negative Factors
No demonstrated revenue base
Zero reported revenue across periods shows that the business has not yet demonstrated commercial traction from its product candidates or intellectual property. Without an operating revenue base, near-term progress remains dependent on development success, commercialization, licensing, or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Drug-delivery and therapeutic R&D platform
A focused portfolio spanning therapeutic formulations and delivery technologies provides multiple routes to future commercialization, licensing, or partnering. If development milestones are achieved, this platform could create intellectual-property value beyond any single product candidate over the next several quarters.
Read all positive factors
PreveCeutical Medical (PREV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$15.95M
Dividend YieldN/A
Average Volume (3M)170.29K
Price to Earnings (P/E)―
Beta (1Y)-0.39
Revenue GrowthN/A
EPS Growth-36.36%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding638,186,950
10 Day Avg. Volume270,812
30 Day Avg. Volume170,287
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PreveCeutical Medical Business Overview & Revenue Model
Company Description
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid...
How the Company Makes Money
PreveCeutical Medical’s ability to generate revenue is primarily tied to commercialization of its product candidates and monetization of its intellectual property, including potential licensing or partnering arrangements for its drug-delivery tech...
PreveCeutical Medical Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.24K | -14.43K | -10.10K | -9.86K | -9.89K | -5.09K |
| EBITDA | -272.46K | -1.35M | -837.46K | -955.09K | -1.23M | -829.83K |
| Net Income | -687.11K | -1.58M | -1.17K | -1.27M | -1.48M | -1.73M |
Balance Sheet | ||||||
| Total Assets | 1.51M | 1.45M | 225.66K | 181.51K | 189.14K | 161.20K |
| Cash, Cash Equivalents and Short-Term Investments | 35.66K | 10.24K | 59.14K | 1.43K | 5.62K | 16.06K |
| Total Debt | 4.84M | 4.68M | 4.46M | 3.89M | 3.23M | 2.93M |
| Total Liabilities | 8.20M | 7.69M | 6.86M | 5.96M | 4.82M | 4.27M |
| Stockholders Equity | -6.69M | -6.24M | -6.64M | -5.78M | -4.64M | -4.10M |
Cash Flow | ||||||
| Free Cash Flow | -1.60M | -1.72M | -428.49K | -296.97K | -222.64K | -481.59K |
| Operating Cash Flow | -1.60M | -1.72M | -426.69K | -296.97K | -222.64K | -426.39K |
| Investing Cash Flow | 57.04K | -2.96K | -1.80K | 0.00 | 850.00 | -52.70K |
| Financing Cash Flow | 1.57M | 1.68M | 487.64K | 293.62K | 211.72K | 136.75K |
PreveCeutical Medical Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.02
Positive
Market Momentum
<0.01
Negative
64.98
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.98 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PREV.
PreveCeutical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$25.67M | -15.77 | -72.15% | ― | 224.46% | 28.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$48.57M | -24.00 | 19.88% | ― | ― | 15.07% | |
47 Neutral | C$15.95M | -20.83 | 10.15% | ― | ― | -36.36% | |
46 Neutral | C$16.37M | -5.04 | 46.54% | ― | 4.30% | 38.28% |
* Healthcare Sector Average
TSE:PREV
PreveCeutical Medical
0.03
-0.01
-28.57%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.12
-0.04
-25.00%
TSE:BETR
BetterLife Pharma
0.30
0.21
252.94%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.24
0.13
123.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.